Lite Strategy

Lite Strategy Accounts Payable

The Accounts Payable of Lite Strategy (LITS) as of Nov 20, 2026 is 261,000.00 USD. In the previous year, Accounts Payable was 176,000.00 USD — a change of 48.30% (higher).

Accounts Payable

261,000.00USD

YoY

48.30%

Last updated:

Accounts Payable of Lite Strategy is 2026 261,000.00 USD. Accounts Payable of Lite Strategy was 2025 176,000.00 USD. It decreases by 48.30% higher compared to the previous year.

The Lite Strategy Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
4.80 M USD
Jan 1, 2020
2.40 M USD
Jan 1, 2021
6.36 M USD
Jan 1, 2022
7.92 M USD
Jan 1, 2023
6.13 M USD
Jan 1, 2024
3.17 M USD
Jan 1, 2025
176,000.00 USD
Jan 1, 2026
261,000.00 USD
The Lite Strategy Accounts Payable history
YEARAccounts PayableYoY
261,000.00USD+48.30%
176,000.00USD-94.44%
3.17 MUSD-48.35%
6.13 MUSD-22.53%
7.92 MUSD+24.59%
6.36 MUSD+164.79%
2.40 MUSD-50.00%
4.80 MUSD+33.33%
3.60 MUSD+500.00%
600,000.00USD-45.45%
1.10 MUSD+22.22%
900,000.00USD-47.06%
1.70 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

Accounts Payable of Lite Strategy is 261,000.00 USD in 2026.

Accounts Payable of Lite Strategy changed from 176,000.00 USD to 261,000.00 USD, representing a 48.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Lite Strategy historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lite Strategy

All Key Metrics — Lite Strategy